Q-Med sees continued weak deliveries to North America and Japan

Q-Med sees continued weak deliveries of esthetic products to North America and Japan during the first quarter of 2008. Deliveries of esthetic products to North America are probably still being affected by the building up of inventories that occurred during the second and third quarters last year. Deliveries to Japan are being affected both by insufficient processing of the market as a consequence of the fact that Q-Med cannot be actively present in the Japanese market and by the fact that sales to one of the major customers are still being affected negatively as a consequence of the customer’s previous payment problems.

The continued weak development with regard to deliveries to these markets in combination with continued investments in marketing and sales has affected income for the first quarter negatively.

It is estimated that Q-Med’s total sales were 289 MSEK during the first quarter and that operating income was 10 MSEK.

Investments in marketing and sales comprise amongst other things the launch of Macrolane™ and increased sales work in the European market.

In the longer term, however, Q-Med is positive to how the market and demand for Q-Med’s products will develop. Q-Med’s overall objective is continued high growth together with good profitability.


Queries should be addressed to:
Bengt Ågerup, President and CEO
Tel: +46 (0)70-974 9025
Alexander Kotsinas, CFO
Tel: +46 (0)70-974 9020
Madelene Sandgren, Director Investor Relations and Corporate Communications
Tel: +46 (0)70-974 9015

Q-Med’s interim report January-March will be published April 29.

The information was submitted for disclosure at 7.55 a.m. on April 11.